Navigation Links
Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
Date:6/27/2011

s the leading cause of hospitalization in Americans 65 years of age and older.

Additionally, the 12-month CUPID data show that heart failure, which is a progressive disease, became stabilized in high dose MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function essentially improved or remained the same while these parameters deteriorated substantially in patients treated with placebo and concurrent optimal drug and device therapy.

The safety profile from this study was very favorable, with no significant side-effects from MYDICAR therapy.

Roger Hajjar, M.D., Director, Cardiovascular Research Center, Mount Sinai School of Medicine, NY, and co-founder of Celladon said: "While conventional treatment modalities have reduced heart failure mortality in the last 20 years, there remains a critical need for new therapeutic approaches in patients with advanced heart failure. The successful and safe completion of the phase 2 CUPID trial may give patients with heart failure a new therapeutic option in the future."

The CUPID Trial

The CUPID trial (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MYDICAR, a genetically targeted enzyme replacement therapy for advanced heart failure. Enrolled patients had severe forms of the disease defined by New York Heart Association Class III or IV heart failure, significantly impaired pumping function of their hearts (ejection fraction less than or equal to 35 percent), and less than half the normal ability to transport and utilize oxygen during exercise testing (VO2max less than or equal to 20 mL/kg/min). The CUPID trial ClinicalTrials.gov Identifier is NCT00454818.

Primary outcome measures included safety, worsening of heart failure leading to hospitalization, fr
'/>"/>

SOURCE Celladon Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
2. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
3. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
4. Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation
5. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
6. China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results
7. Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A.
8. Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children
9. Geminus Corporation Named Recipient of Second Annual Netsmart Technologies Customer Innovation Award
10. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
11. DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... March 29, 2011 Perceptive Informatics , a ... International Corporation (Nasdaq: PRXL ), today unveiled ... (EDC) solution, which provides richer functionality to further streamline ... solution enables clinical trial sponsors to more efficiently ...
... MP3s, smartphones and cameras could become a reality thanks ... a tiny device that improves on existing forms of ... to convert data into signals that are stored as ... arm to translate the data into electrical signals. This ...
... MARIETTA, Ga., March 28, 2011 MiMedx Group, Inc. ... developer, manufacturer and marketer of patent protected biomaterial-based products ... its results for the year ended December 31, 2010. ... Company changed its fiscal year to coincide with the ...
Cached Biology Technology:Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 2Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 3Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 4Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 5MiMedx Group Announces 2010 Results 2MiMedx Group Announces 2010 Results 3MiMedx Group Announces 2010 Results 4MiMedx Group Announces 2010 Results 5MiMedx Group Announces 2010 Results 6MiMedx Group Announces 2010 Results 7
(Date:7/11/2014)... Shenzhen, China Researchers from Salk Institute for Biological ... time evaluated the safety and reliability of the ... a new method, TALEN-HDAdV, which could significantly increased ... (hiPSC). This study published online in Cell ... for stem cell-based gene therapy. , The combination ...
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
(Date:7/11/2014)... SEATTLE, WASH. July 11, 2014 Researchers ... navigate three-dimensional images. The new technology, called Virtual ... of small structures like neurons and synapses using ... Finger,s unique technology makes 3D imaging studies orders ... resources at an unprecedented level across many areas ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... pathway that Cannabis sativa uses to create bioactive compounds ... marijuana varieties to produce pharmaceuticals or cannabinoid-free industrial hemp. ... edition of the Proceedings of the National Academy ... professor of biology Jon Page explains that the pathway ...
... R.I. A Rhode Island Hospital researcher has found ... behaviors such as alcohol use, unsafe sex and violence. ... messaging, email, or Internet) over traditional intervention methods such ... Megan L. Ranney, M.D., is available now online in ...
... waste time and money while reducing print quality. University of ... the human eye. "The nozzle cover we invented ... associate professor in the College of Engineering. "The eye and ... not be allowed to dry while, simultaneously, they must open. ...
Cached Biology News:U of S researchers discover cannabis 'pharma factory' 2RIH study: Emergency patients prefer technology-based interventions for behavioral issues 2Human eye inspires clog-free ink jet printer invented by MU researcher 2
... Immunogen corresponds to amino acids 2-105 from ... been successfully used in Western blot, immunocytochemistry ... this antibody detects an ~ 60 kDa ... also been used in immunoprecipitation and immunocytochemical ...
Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
... a new tuning and calibration standard for ... Accumix is a lyophilized 7-peptide standard ... both tuning and calibration of ion trap ... transform mass spectrometers. Direct infusion of ...
... White crystalline solid. HYGROSCOPIC. Water-soluble zwitterionic detergent ... 252005) but differing in the length of ... extraction of mycoplasma membrane antigens under mild ... TLC. Soluble in H 2 O. ...
Biology Products: